CU Medical Systems Inc (115480) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of CU Medical Systems Inc KRW 6,677, price KRW 2,290, upside +191.6%, quality 76 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range 1,705 KRW – 8,991 KRW · fair‑value band 5,182 KRW – 8,489 KRW · the 2,290 KRW price screens below the 6,677 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 4, 2026.
Follow CU Medical Systems in your weekly email
Every Wednesday you see whether CU Medical Systems is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CU Medical Systems, Inc. manufactures and sells defibrillators worldwide. The company offers automatic external defibrillators (AEDs), mechanical cardiopulmonary resuscitation systems, healthcare and rehabilitation products, AED trainers, and sterilizers/disinfectors. It also resells Apple products, including Mac, iPad, and iPod.
Show more
CU Medical Systems, Inc. manufactures and sells defibrillators worldwide. The company offers automatic external defibrillators (AEDs), mechanical cardiopulmonary resuscitation systems, healthcare and rehabilitation products, AED trainers, and sterilizers/disinfectors. It also resells Apple products, including Mac, iPad, and iPod. The company was founded in 2001 and is headquartered in Wonju-si, South Korea.
Stock analysis
CU Medical Systems Inc (115480) currently trades at 2,290 KRW, while our model-based Fair Value estimate is 6,677 KRW, implying the stock looks roughly 65.7% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 9,109 KRW per share, and 17 of the 24 models we run sit above the 2,290 KRW price.
Bear case: the Growth Earnings group reads lowest at 999.82 KRW, and 7 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 5,182 KRW (bear) to 8,489 KRW (bull), the price of 2,290 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CU Medical Systems Inc reported revenue of 48.2B KRW in FY2025 versus 35.4B KRW in FY2021, a compound +8.0%/yr. Reported net income was 819M KRW in FY2025.
Key figures
Market cap 27.7B KRW (≈ $20.6M) · P/S ratio 0.62 · Net margin 1.7% · Return on equity −693% · Return on assets (EBIT) 6.0% · Operating margin 23.9% · Revenue (TTM) 45.0B KRW · Revenue growth (YoY) +56.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 192%, 115480 screens cheaper than that median.
Fair Value models
Bear 5,182 KRWFair Value 6,677 KRWBull 8,489 KRW
Price 2,290 KRW · Upside +191.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Start year 2020 (pandemic). Over 10 years: +6.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−31.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.1%
Dividend (yield on the price)0.0%
Profit margin 2017 to 2022 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 22%
⚠ Revenue per share shrinking 17.6%/yr over ~7Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−19.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −20.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2415 stocks
Beats the sector median on 6/8 measures
Overall it ranks above its sector peers.
Valuation
Quality Score76 · Top 25%
Fair Value upside+191.6% · Top 25%
Profitability
Return on assets7.8% · Top 25%
Net margin (TTM)−6.5% · Bottom 25%
Operating margin (TTM)23.9% · Top 25%
Growth and dividend
Revenue growth56.9% · Top 25%
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CU Medical Systems Inc Fair Value". https://www.fairvalue-calculator.com/stock/115480
Frequently asked questions
Is CU Medical Systems Inc (115480) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 6,677 KRW versus a price of 2,290 KRW, about +192% upside (undervalued).
What is the fair value of 115480?
Our model-based fair value for CU Medical Systems Inc is 6,677 KRW (as of Oct 4, 2026), built from audited fundamentals. The current price: 2,290 KRW.
What is the quality score of 115480?
CU Medical Systems Inc has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CU Medical Systems Inc (115480)?
Our model-based price target is the fair value of 6,677 KRW (as of Oct 4, 2026) from 24 valuation models. Cautious scenario 5,182 KRW, optimistic scenario 8,489 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the CU Medical Systems Inc stock forecast for 2026?
Our models put fair value at 6,677 KRW, about +192% upside versus a price of 2,290 KRW (undervalued). Cautious scenario 5,182 KRW, optimistic scenario 8,489 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CU Medical Systems Inc (115480)?
CU Medical Systems Inc reported trailing-twelve-month revenue of about 45.0B KRW (latest available figure, as of Oct 4, 2026).
What growth is priced into CU Medical Systems Inc (115480)?
For today's price to be fair in a discounted-cash-flow model, CU Medical Systems Inc would have to grow free cash flow by -19.2 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.2 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of 115480 use?
Our models discount CU Medical Systems Inc at 9.3 %: a base by market capitalisation (nano), damped by beta 0.68, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CU Medical Systems Inc that is -19.2 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has CU Medical Systems Inc (115480) delivered so far?
Over the past 5 years revenue at CU Medical Systems Inc grew +11.2 % a year. The price currently implies -19.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CU Medical Systems Inc (115480) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into CU Medical Systems Inc (-19.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CU Medical Systems Inc (115480)?
The free-cash-flow yield on the price is 32.15 %: that much free cash flow CU Medical Systems Inc produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CU Medical Systems Inc (115480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CU Medical Systems Inc it is 6,677 KRW per share (as of Oct 4, 2026), against a price of 2,290 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is CU Medical Systems Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 115480 trades below its calculated fair value: price 2,290 KRW, fair value 6,677 KRW, a gap of about +192% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 115480?
No. The price is what the market pays today (2,290 KRW); the fair value is what the company's own numbers justify (6,677 KRW). For CU Medical Systems Inc the two are 4,387 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CU Medical Systems Inc worth?
The market values CU Medical Systems Inc at about 27.7B KRW (market capitalisation, as of Oct 4, 2026). Per share that is 2,290 KRW; our models calculate a fair value of 6,677 KRW per share.
What do the bullish and bearish scenarios say about 115480?
Our models span a range for CU Medical Systems Inc: cautious scenario 5,182 KRW, base 6,677 KRW, optimistic 8,489 KRW per share (as of Oct 4, 2026, price 2,290 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CU Medical Systems Inc (115480)?
Balance-sheet figures for CU Medical Systems Inc (as of Oct 4, 2026): debt of 0.46 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is 115480 from its 52-week high?
CU Medical Systems Inc trades at 2,290 KRW, about 29% below its 52-week high of 3,220 KRW and 34% above the low of 1,705 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 6,677 KRW is for.
Which stocks are comparable to CU Medical Systems Inc?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Meta Biomed Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CU Medical Systems Inc stock attractive at the current price?
The data as of Oct 4, 2026: price 2,290 KRW, calculated fair value 6,677 KRW (+192%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 115480 calculated?
We run CU Medical Systems Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6,677 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. CU Medical Systems Inc currently trades 66 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CU Medical Systems Inc (115480)?
The closing price on Oct 2, 2026 was 2,290 KRW. Our model-based fair value is 6,677 KRW, about +192% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CU Medical Systems Inc right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (5,182 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of CU Medical Systems Inc
How large is the market capitalisation of CU Medical Systems Inc (115480)?
The market capitalisation of CU Medical Systems Inc is 27.7B KRW (≈ $20.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CU Medical Systems Inc (115480)?
The price-to-sales ratio of CU Medical Systems Inc is 0.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of CU Medical Systems Inc (115480)?
The net margin of CU Medical Systems Inc is 1.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CU Medical Systems Inc (115480)?
The return on equity (ROE) of CU Medical Systems Inc is −693% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CU Medical Systems Inc (115480)?
On an EBIT basis the return on assets of CU Medical Systems Inc is 6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CU Medical Systems Inc (115480)?
The operating margin of CU Medical Systems Inc is 23.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CU Medical Systems Inc (115480)?
Revenue at CU Medical Systems Inc is growing +56.9% versus a year earlier (3y avg +0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CU Medical Systems Inc (115480)?
Earnings per share at CU Medical Systems Inc are growing +16.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CU Medical Systems Inc (115480) carry?
The net debt of CU Medical Systems Inc is 13.7B KRW (fiscal year 2025, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CU Medical Systems Inc in the live analysis
One click puts CU Medical Systems Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
